Last €11.33 EUR
Change Today +0.337 / 3.07%
Volume 70.0
AB3A On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 9:34 AM 12/29/14 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Edward M. Kaye M.D., Ph.D.

Chief Medical Officer and Senior Vice President, Sarepta Therapeutics, Inc.
AgeTotal Calculated CompensationThis person is connected to 7 board members in 1 different organizations across 2 different industries.

See Board Relationships
65$2,648,950
As of Fiscal Year 2013

Background*

Dr. Edward M. Kaye, also known as Ed, M.D. Ph.D. has been the Chief Medical Officer and Senior Vice President of AVI BioPharma Inc. since June 20, 2011. Dr. Kaye serves as a Neurological Consultant at Children's Hospital of Boston. He has specific experience with pediatric neuromuscular conditions. Dr. Kaye joined AVI from Genzyme, where he served as Group Vice President for Clinical Development and Therapeutic Head for Lysosomal Storage Disorders and Neurodegenerative ...

Read Full Background

Corporate Headquarters*

215 First Street
Cambridge, Massachusetts 02142

United States

Phone: 857-242-3700
Fax: --

Board Members Memberships*

There is no Board Members Memberships data available.

Education*

Unknown/Other Education
Boston University
MD
Stritch School Of Medicine, Loyola University
BS
Loyola University of Chicago

Other Affiliations*

Annual Compensation*

Salary$377,650
Total Annual Compensation$377,650

Stock Options*

All Other Compensation$17,797
Exercisable Options119,607
Exercisable Options Value$1,412,275
Unexercisable Options157,412
Unexercisable Options Value$1,283,329
Total Value of Options$2,695,603
Total Number of Options322,019

Total Compensation*

Total Annual Cash Compensation$562,660
Total Short Term Compensation$377,650
Other Long Term Compensation$17,797
Total Calculated Compensation$2,648,950
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AB3A:GR €11.33 EUR +0.337

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
John C. Martin Ph.D.Chairman and Chief Executive Officer
Gilead Sciences Inc.
$1.6M
William A. Carter M.D.Chairman, Chief Executive Officer, President, Chief Scientific Officer, Chairman of Executive Committee, Member of Strategic Planning Committee and Member of Disclosure Controls Committee
Hemispherx Biopharma, Inc.
$1.0M
Robert L. Parkinson Jr.Chairman, Chief Executive Officer and President
Baxter International Inc.
$1.5M
Friedhelm Blobel Ph.D.Chief Executive Officer, President, Executive Director and Member of Business Development Committee
SciClone Pharmaceuticals, Inc.
$550.0K
Pascal Soriot Chief Executive Officer, Executive Director and Member of Disclosure Committee
AstraZeneca PLC
3.0M GBP
Compensation as of Fiscal Year 2013.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SAREPTA THERAPEUTICS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.